Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069309

SCHEMBL21069309

SCHEMBL21069309

OCCOCCCCOC1CCCCO1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ KDM4C Q9H3R0 1/20 0.39
▸ THRB P10828 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TSHR P16473 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ PDK1 Q15118 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609455 1.00 MEN1 (0.49) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL24574135 0.98 MEN1 (0.48) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL22787022 0.97 MEN1 (0.50) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL24574176 0.97 MEN1 (0.47) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL24574137 0.97 MEN1 (0.47) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL27269433 0.97 MEN1 (0.50) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL22070790 0.93 KMT2A (0.49) MEN1KMT2AKDM4CTSHRL3MBTL1
SCHEMBL20128999 0.93 KMT2A (0.49) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL578640 0.93 MEN1 (0.43) MEN1KMT2AKDM4CTHRBHTT
SCHEMBL12286917 0.93 MEN1 (0.43) MEN1KMT2AKDM4CTHRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 — — EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 — — CN disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 MEN1 1907/4885KMT2A 813/4885KDM4C 480/4885
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 MEN1 1907/4885KMT2A 813/4885KDM4C 480/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.